ImmunoGen Inc. (IMGN) Closes at $3.73, Underpriced by 20.13%

Publicly-traded company ImmunoGen Inc. (NASDAQ:IMGN) had a closing price of $3.73 yesterday. Meanwhile, the average 12-month price target from Wall Street analysts is currently $4.67, this means that the stock is underpriced by 20.13%. In the past 52 weeks the company’s stock price has moved within the range of $1.76 to $6.47.

This particular stock’s 5-day moving average is 2.93, its 20-day moving average is 2.63 and its 100-day moving average is 2.57. ImmunoGen Inc. (IMGN) currently has 117.34M shares outstanding, which means that its market capitalization is $438.26M.

The Details: ImmunoGen Inc. (IMGN) Financial Health

We can also find the company’s Return on Assets, which is a percentage that shows us how well a company uses its current assets to make a profit. The larger the score, the better. At the moment, ImmunoGen Inc. Return on Assets is -56.40%.

What Does Wall Street Say about Company?

When considering a stock buy, many investors seek to know what Wall Street analysts are saying about the company – by looking at the average analyst rating, for example. At the moment, the average analyst rating for IMGN is Overweight. Out of 9 total analysts who were surveyed, 1 rated it a sell, 0 rated it a underweight, 0 rated it an overweight, 4 rated it hold, and 4 rated it a Buy.

Three months ago, on the other hand, the average analyst rating for ImmunoGen Inc. (IMGN) was a Overweight – from a survey of 11 analysts. Of the analysts who provided ratings, 6 rated the company a Hold, 1 rated it a Sell, 0 rated it an overweight, 0 rated it an underweight, and 4 rated it a Buy.

Understanding Profitability at ImmunoGen Inc. (IMGN)

A smart way of assessing a company’s profitability is by checking out its latest Earnings per Share (EPS). In the most recent financial results released by ImmunoGen Inc., for the quarter ending on 12/2019, the company posted EPS of -0.12. The average estimate of Wall Street analysts had projected -0.03.

Wall Street analysts, on average, are forecasting the company’s EPS to be -0.15, compared to -0.28 reported in the same quarter last year. When it comes to net revenue, the average estimate from a total of 10 analysts is 27.75M – compared to 13.79M posted in the year-ago period.